Exceptionally Large and Innovative Pipeline
The breast cancer pipeline is the largest in the pharmaceutical industry with 815 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations in this pipeline is exceptional; GBI Research analysis identified 253 first-in-class programs in the breast cancer pipeline, acting on 176 first-in-class molecular targets.
Browse complete report with TOC:
http://www.reportsandintelligence.com/frontier-pharma-breast-cancer-identifying-and-commercializing-first-in-class-innovation-market
